Cancer Cell

Article	Citations
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth	929
Conserved pan-cancer microenvironment subtypes predict response to immunotherapy	663
The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker	645
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities	532
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments	394
CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4	392
Proteogenomic and metabolomic characterization of human glioblastoma	386
Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer	358
Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation	346
Challenges and Opportunities for Pancreatic Cancer Immunotherapy	344
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma	341
Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer	338
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade	311
Microbiome and cancer	302
Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma	302
Seroconversion rates following COVID-19 vaccination among patients with cancer	285
Targeting cell-cycle machinery in cancer	285
Progressive immune dysfunction with advancing disease stage in renal cell carcinoma	267
Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver	258
Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma	255
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial	245
Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer	238
Artificial intelligence for multimodal data integration in oncology	231
YTHDF3 Induces the Translation of m6A-Enriched Gene Transcripts to Promote Breast Cancer Brain Metastasis	230
Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies	223

Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy	221
Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer	219
Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma	219
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer	218
Immunometabolic Interplay in the Tumor Microenvironment	216
Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity	203
Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification	203
Immune phenotypic linkage between colorectal cancer and liver metastasis	202
Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade	202
Pan-cancer integrative histology-genomic analysis via multimodal deep learning	198
Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states	196
Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL	193
Biomolecular Condensates and Cancer	192
Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer	189
Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations	189
Mutant p53 suppresses innate immune signaling to promote tumorigenesis	189
Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer	189
Artificial intelligence for clinical oncology	178
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity	177
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma	175
DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity	173
Metabolic programming and immune suppression in the tumor microenvironment	173
Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma	170
An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence	170
Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence	167
Single-Cell Multiomics Sequencing Reveals Prevalent Genomic Alterations in Tumor Stromal Cells of Human Colorectal Cancer	167
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy	166
Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer	166
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial	162
Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer	162
Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer	155
Tumor organoids: Opportunities and challenges to guide precision medicine	155
High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer	155
Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site	154
Immunomodulation by targeted anticancer agents	153
The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth	151
Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy	150
Activating a collaborative innate-adaptive immune response to control metastasis	149
N6-Methyladenosine on mRNA facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiation	147
Oncogenic extrachromosomal DNA functions as mobile enhancers to globally amplify chromosomal transcription	147
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma	144
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms	144
Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations	143
The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer	143
Reuterin in the healthy gut microbiome suppresses colorectal cancer growth through altering redox balance	141
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia	137
Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistance	135
Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy	135
The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma	134
The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1	134

Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance	133
Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer	133
Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer	129
MLH1 Deficiency-Triggered DNA Hyperexcision by Exonuclease 1 Activates the cGAS-STING Pathway	129
Evaluation of cell-free DNA approaches for multi-cancer early detection	128
Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment	127
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies	127
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress	123
MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage	122
Melanoma models for the next generation of therapies	122
Spatial profiling technologies illuminate the tumor microenvironment	120
Integrin αvβ6–TGFβ–SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer	119
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study	117
Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion	114
The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia	113
Targeting pan-essential genes in cancer: Challenges and opportunities	113
MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells	111
Cancer cells escape autophagy inhibition via NRF2-induced macropinocytosis	110
Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity	107
Activated fibroblasts in cancer: Perspectives and challenges	104
Pan-cancer proteomic map of 949 human cell lines	101
Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance	101
Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia	100
PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity	98
Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity	98
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor	98
Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer	95
Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin	94
Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma	94
A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers	92
IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer	92
The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients	91
Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients	90
Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy	88
NETworking with cancer: The bidirectional interplay between cancer and neutrophil extracellular traps	88
Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-β activation	87
Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis	87
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation	86
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer	86
Serial assessment of measurable residual disease in medulloblastoma liquid biopsies	85
The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support	84
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness	83
Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells	83
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance	82
Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective	81
The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance	80
Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy	80
Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer	80
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies	80
Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies	79
Molecular classification and diagnostics of upper urinary tract urothelial carcinoma	79
Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer	78
Cancer hallmarks intersect with neuroscience in the tumor microenvironment	77
GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity	76
Functional states of myeloid cells in cancer	76
Single-cell landscapes of primary glioblastomas and matched explants and cell lines show variable retention of inter- and intratumor heterogeneity	76
Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function	75
Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis	75
The proteogenomic subtypes of acute myeloid leukemia	75
Tumor microbiome links cellular programs and immunity in pancreatic cancer	74
Transcriptome analysis reveals tumor microenvironment changes in glioblastoma	74
Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment	74
From bench to bedside: Single-cell analysis for cancer immunotherapy	73
Tumor heterogeneity	72
Clearance of senescent macrophages ameliorates tumorigenesis in KRAS-driven lung cancer	72
KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells	72
Innate immune cells in the tumor microenvironment	71
Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma	71
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)	70
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia	69
Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers	69
Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes	67
Interferon-dependent SLC14A1+ cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer	67
STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma	67
Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer	66
The therapeutic window of antibody drug conjugates: A dogma in need of revision	65
Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop	65
Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy	65
B cells and cancer	65
Interleukin-1 in tumor progression, therapy, and prevention	64

H3.3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model	63
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma	63
TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma	63
Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy	62
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors	61
B cells in the tumor microenvironment: Multi-faceted organizers, regulators, and effectors of anti-tumor immunity	61
FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer	60
NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer	60
Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy	60
Clinical application of advanced multi-omics tumor profiling: Shaping precision oncology of the future	60
Neutrophil-activating therapy for the treatment of cancer	60
Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma	60
Senescent alveolar macrophages promote early-stage lung tumorigenesis	59
STAG2 mutations alter CTCF-anchored loop extrusion, reduce cis-regulatory interactions and EWSR1-FLI1 activity in Ewing sarcoma	59
YTHDF2 inhibition potentiates radiotherapy antitumor efficacy	58
Exhaustion-associated cholesterol deficiency dampens the cytotoxic arm of antitumor immunity	58
Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells	57
Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy	57
Epithelial cells activate fibroblasts to promote esophageal cancer development	56
A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy	56
Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment	56
Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients	56
Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study	54
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity	54
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity	54
COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer	54
Transformer-based biomarker prediction from colorectal cancer histology: A large-scale multicentric study	53
A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity	53
Squamous cell lung cancer: Current landscape and future therapeutic options	51
Proteogenomic data and resources for pan-cancer analysis	51
Immune determinants of the pre-metastatic niche	51
Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses	50
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas	50
The translational challenges of precision oncology	50
High-performance multiplex drug-gated CAR circuits	50
Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer	50
New genomic technologies for multi-cancer early detection: Rethinking the scope of cancer screening	49
Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer	49
Detection and localization of early- and late-stage cancers using platelet RNA	49
Normal Somatic Mutations in Cancer Transformation	48
Gut microbiota-mediated nucleotide synthesis attenuates the response to neoadjuvant chemoradiotherapy in rectal cancer	48
Challenges in neoantigen-directed therapeutics	48
Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity	48
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer	48
The role of exhaustion in CAR T cell therapy	48